Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Shares Outstanding (Weighted Average) (2016 - 2025)

VYNE Therapeutics' Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $42.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) changed 0.42% year-over-year to $42.8 million; the TTM value through Dec 2025 reached $42.8 million, changed 0.42%, while the annual FY2025 figure was $42.8 million, 0.42% changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $42.8 million in Q4 2025 per VYNE's latest filing, roughly flat from $42.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $51.4 million in Q2 2021 to a low of $2.9 million in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $25.5 million, with a median of $42.6 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 93.75% in 2022, then soared 1208.17% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $2.9 million in 2021, then increased by 11.44% to $3.2 million in 2022, then surged by 222.44% to $10.3 million in 2023, then soared by 314.57% to $42.6 million in 2024, then rose by 0.42% to $42.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Shares Outstanding (Weighted Average) are $42.8 million (Q4 2025), $42.8 million (Q2 2025), and $42.7 million (Q1 2025).